Artículos de revistas
Predictive value of galectin-1 in the development and progression of HIV-associated lymphoma
Fecha
2017-10-23Registro en:
Vase, MajaØlholm; Ludvigsen, Maja; Bendix, Knud; Dutoit, Stephen H.; Hjortebjerg, Rikke; et al.; Predictive value of galectin-1 in the development and progression of HIV-associated lymphoma; Lippincott Williams; Aids; 31; 16; 23-10-2017; 2311-2313
0269-9370
CONICET Digital
CONICET
Autor
Vase, MajaØlholm
Ludvigsen, Maja
Bendix, Knud
Dutoit, Stephen H.
Hjortebjerg, Rikke
Petruskevicius, Irma
Møller, Michael B.
Pedersen, Gitte
Denton, Paul W.
Honoré, Bent
Rabinovich, Gabriel Adrián
Larsen, Carsten S.
D'Amore, Francesco
Resumen
At AHIV-1 infection, the binding of the viral envelopeproteins to CD4þ is essential for viral transmission, andthis process is facilitated by interaction with the highlyconserved host lectin, galectin-1 (Gal-1) [1?3]. Withinthe tumor microenvironment, Gal-1 is expressed by bothtumor and stromal cells where it promotes tumorimmune escape and favors hypoxia-driven angiogenesis[4?6]. In sporadically occurring Hodgkin lymphoma,high Gal-1 expression at diagnosis is associated withpoorer treatment response [7], and high soluble Gal-1(sGal-1) correlates with adverse disease characteristics [8].Previous studies have shown that targeted inhibition ofGal-1 prevents tumor-induced immunosuppression[9,10] as well as inhibits tumor growth and metastasisin various tumor models [6,11?13].In conclusion, the results of our study indicate that Gal-1 is significantly associated with risk of lymphoma in HIV-infected individuals and may represent an attractive futuretarget for the management of HIV-associated lymphoma.